Cancer is one of the major causes of death worldwide as more than half of the patients are diagnosed during advanced metastatic phases. Considering its gravity, this problem needs to be addressed promptly. A novel plasmonic sensor is developed by researchers at the University of Illinois that can serve as a reliable tool for early detection of biomarkers for various forms of cancer and eventually other comorbidities.
According to the researchers, the novel plasmonic sensor has been proven reliable to detect the presence of the cancer biomarker carcinoembryonic antigen (CEA), which is a glycoprotein normally found in the embryonic entodermal epithelium. CEA is the second most common serum biomarker currently used clinically to detect the various type of carcinoma. Although there are complementary clinical data, elevated CEA levels have been established as an independent predictor of…
